the pharmaceutical industry part 2
Download
Skip this Video
Download Presentation
The Pharmaceutical Industry Part 2

Loading in 2 Seconds...

play fullscreen
1 / 35

The Pharmaceutical Industry Part 2 - PowerPoint PPT Presentation


  • 188 Views
  • Uploaded on

The Pharmaceutical Industry Part 2. Professor Vivian Ho Health Economics Fall 2007. Pharmaceutical Industry Conduct. Pricing Does more intense competition   drug prices? Promotion Does drug advertising promote or impede competition? Product innovation

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about 'The Pharmaceutical Industry Part 2' - agrata


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
the pharmaceutical industry part 2

The Pharmaceutical IndustryPart 2

Professor Vivian Ho

Health Economics

Fall 2007

pharmaceutical industry conduct
Pharmaceutical Industry Conduct
  • Pricing
    • Does more intense competition   drug prices?
  • Promotion
    • Does drug advertising promote or impede competition?
  • Product innovation
    • Are large firms necessary for drug innovation?
  • Preview: Empirical evidence indicates that competition is at work, but the industry does not exhibit perfect competition.
pricing behavior
Pricing Behavior
  • Can the brand-name firm maintain its price once its patent expires and generics enter?
    • After patent expiration, each 10% increase in the price differential for brand-name drugs relative to generics resulted in only a .5% drop in market share for the brand-name drug. (Hurwitz & Caves, 1988)
    • Average price differential between brand-name and generic firms = 127%, but brand name market share = 63.4%.
pricing behavior4
Pricing Behavior
  • The longer the brand-name drug’s effective patent length, the more market share it preserved after patent expiration.
  • The arrival of an additional supplier was estimated to reduce the brand-name drug’s market share by 1.25 percentage points.
pricing behavior5
Pricing Behavior
  • Branded drugs’ prices 11% 2 years after generic entry. (Grabowski & Vernon 1992)
    • Yet brand-name drugs lost 1/2 of market share.
    • Average market price fell to 79% of pre-entry price.
pricing behavior6
Pricing Behavior
  • Brand-name firms segment the market.
    • Remaining customers relatively price insensitive.
    • Inelastic demand curve allows them to maintain price.
  • These 2 studies suggest that generic drug prices are substantially lower than brand-name prices.
promotion strategies
Promotion Strategies
  • Promotion Magnitude:
    • Research-base firms spend as much as 20-30% of sales on promotion.
    • 70% pharmaceutical salespersons (detailing).
    • 27% advertising.
    • 3% direct mail.
  • Impact:
    • 22,000 drugs on market  timely, valuable information.
    • May impede competition.
direct to consumer prescription drug advertising bane or boon

Direct-to-Consumer PrescriptionDrug Advertising: Bane or Boon?

Richard L. Kravitz, MD, MSPH

UC Davis Center for Health Services Research in Primary Care

a brief regulatory history
A brief regulatory history
  • 1981: industry shows interest in advertising directly to consumers
  • 1983–1985: FDA obtains voluntary moratorium on DTC advertising
    • 1985: moratorium lifted
  • 1990: DTC advertising begins in earnest
  • 1997: TV advertising made feasible through FDA policy change
ads are read and acted upon
Ads are read and acted upon
  • 56% of Sacramento-area adults have read a DTC ad carefully from beginning to end
  • 35% have asked their doctor for more information because of a DTC ad
  • 19% have asked for a prescription due to an ad
misconceptions abound
Misconceptions abound
  • 50% believe ads subject to prior review
  • 43% believe only “completely safe” prescription drugs can be marketed DTC; 21% that only “extremely effective” drugs can be so marketed
  • 22% believe that advertising of prescription drugs with serious side effects has been banned
the industry perspective
The Industry Perspective

“ By greatly increasing the likelihood that patients will seek help for their medical problems and receive a safe and effective prescribed medicine, DTC advertising will…play a very real role in enhancing public health.”

-Alan F. Holmer, President, Pharmaceutical Research and Manufacturers of America, JAMA 281:380,1999

a contrarian view
A Contrarian View

“Extending the scope of already ubiquitous promotions about ‘post-nasal drip,’ ‘unsightly rashes,’ or ‘cures for baldness’ has little to do with educating patients or relieving suffering. It will, however, inevitably drain healthcare dollars, dramatically increase unnecessary prescribing, and strain patient-doctor relationships.”

--JR Hoffman and MS Wilkes, BMJ 318:1301, 1999

content analysis of print ads
Content analysis of print ads
  • All DTC ads appearing from 1989 through 1998 in 18 popular magazines
  • Selection of publications based on circulation
influence on prescribing decisions a bi national study
Influence on prescribing decisions: a bi-national study
  • Cross-sectional cluster survey in Sacramento (CA) and Vancouver (CANADA)
  • 78 primary care physicians
  • 1431 patients (61% of those attending on preset clinic days)
patient requests and physician prescribing
Patient requests and physician prescribing
  • Patients requested prescriptions in 12% of visits (MD report)
  • 42% of requests were for advertised products
  • 74% of those requesting drugs received them (similar for advertised and non-advertised drugs)
  • Patients requesting a prescription much more likely to receive one (AOR 8.7, 95% CI 5.4-14.2)
provoking clinical ambivalence
Provoking clinical ambivalence
  • “If you were treating another similar patient with the same condition, would you prescribe this drug?”
  • Percent “possibly” or “unlikely”
    • Rx not requested: 13%
    • Any drug requested: 49%
    • Advertised drug requested: 70%
summary of katz studies
Summary of Katz Studies
  • DTC ads are reaching consumers
  • Education is a side effect of promotion
  • DTCA-induced requests influence prescribing
  • A true reckoning of public health benefits and harms has not occurred
product innovation26
Product Innovation

www.phrma.org

product innovation27
Product Innovation
  • Innovation is very risky and time consuming.
    • R&D process takes many years.
    • Only a small fraction of new drug discoveries are eventually marketed.
    • 75% of NCEs in Phase 1 go to Phase 2.
    • 36% of NCEs in Phase 1 go to Phase 3.
capitalized cost per approved drug
Capitalized Cost perApproved Drug
  • R&D costs are capitalized to the date of marketing approval
  • The cost-of-capital is based on a CAPM analysis of the pharmaceutical industry
  • An 11% real cost-of-capital was utilized for the period under study
out of pocket and capitalized costs per approved drug
Out-of-Pocket and Capitalized Costsper Approved Drug

802

466

403

336

282

121

J. DiMasi, R. Hansen, and H. Grabowski, “The Price of Innovation: New Estimates of Drug Development Costs”, Jan 2002

pharmaceutical industry performance
Pharmaceutical Industry Performance

Does the absence of perfect competition higher prices & restricted output?

*2000 onwards includes prescription drugs and medical supplies.

cautionary note on inflation
Cautionary note on inflation
  • The inflation rate calculated by BLS is based on a price index, which may overstate the true  in drug costs.
  • Price index
    • the relative cost of purchasing a fixed “basket” of drugs in year t, vs. the costs of same basket in a base period.

Price Indext =

cautionary note on inflation33
Cautionary note on inflation
  • BLS “basket” undersamples new drug products, which generally have smaller price increases than older drugs.
  • BLS treats generics as new products, not as substitutes for more expensive drugs.
  • BLS uses list rather than transactions prices.
  • BLS doesn’t adjust prices to reflect quality improvements.
slide34

Are profits in the drug industry “too high?”

The Pharmaceutical industry ranked 7 out of 74 industries with an ROA of 9.9.

are profits in the drug industry too high
Are profits in the drug industry too high?
  • Under standard accounting practices, R&D is written off as a current expense.
  • But R&D affects revenues for years to come.
    • Rate of return on investment is calculated using an asset base that improperly excludes intangible R&D.
    • Should capitalize R&D outlays & depreciate them over appropriate time periods.
    • Accounting figures overstate the rate of return on assets for drug companies.
ad